Gut-lung axis and dysbiosis in COVID-19

Öz COVID-19, a novel infectious disease, caused by SARS-CoV-2, affected millions of people around the world with a high mortality rate. Although SARS-CoV-2 mainly causes lung infection, gastrointestinal symptoms described in COVID-19 patients and detection of the viral RNA in feces of infected patients drove attentions to a possible fecal-oral transmission route of SARS-CoV-2. However, not only the viral RNA but also the infectious viral particles are required for the viral infection and no proof has been demonstrated the transmission of the infectious virus particles via the fecal-oral route yet. Growing evidence indicates the crosstalk between gut microbiota and lung, that maintains host homeostasis and disease development with the association of immune system. This gut-lung interaction may influence the COVID-19 severity in patients with extrapulmonary conditions. Severity of COVID-19 has mostly associated with old ages and underlying medical conditions. Since the diversity in the gut microbiota decreases during aging, dysbiosis could be the reason for older adults being at high risk for severe illness from COVID-19. We believe that gut microbiota contributes to the course of COVID-19 due to its bidirectional relationship with immune system and lung. Dysbiosis in gut microbiota results in gut permeability leading to secondary infection and multiple organ failure. Conversely, disruption of the gut barrier integrity due to dysbiosis may lead to translocation of SARS-CoV-2 from the lung into the intestinal lumen via circulatory and lymphatic system. This review points out the role of dysbiosis of the gut microbiota involving in sepsis, on the severity of SARS-CoV-2 infection. Additionally, this review aims to clarify the ambiguity in fecal-oral transmission of SARS- CoV-2.


Aleman FDD, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007727

Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101

Bajaj Jasmohan S, 2019, Clin Liver Dis (Hoboken), V14, P107, DOI 10.1002/cld.827

Bertok Lorand, 2004, Pathophysiology, V11, P139, DOI 10.1016/j.pathophys.2004.09.002

Burcelin R, 2012, SEMIN IMMUNOL, V24, P67, DOI 10.1016/j.smim.2011.11.011

Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7

Chen YF, 2020, J MED VIROL, V92, P833, DOI 10.1002/jmv.25825

D'Amico F, 2020, CLIN GASTROENTEROL H, V18, P1663, DOI 10.1016/j.cgh.2020.04.001

Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006

Deitch EA, 2012, SURG-J R COLL SURG E, V10, P350, DOI 10.1016/j.surge.2012.03.003

Dickson RP, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.113, 10.1038/NMICROBIOL.2016.113]

Ding SY, 2020, GASTROENTEROLOGY, V159, P53, DOI 10.1053/j.gastro.2020.04.052

Doig CJ, 1998, PNEUMOLOGIE, V52, P441, DOI [10.1164/ajrccm.158.2.9710092, DOI 10.1164/AJRCCM.158.2.9710092]

Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477

Fanos V, 2020, J PEDIATR NEONATAL I, V9, DOI 10.7363/090139

Feng G, 2020, J CLIN TRANSL HEPATO, V8, P18, DOI 10.14218/JCTH.2020.00018

Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234

Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828

Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032

Hanada S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02640

Hickson Mary, 2011, Therap Adv Gastroenterol, V4, P185, DOI 10.1177/1756283X11399115

Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015

Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191

Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5

Hufnagl K, 2020, SEMIN IMMUNOPATHOL, V42, P75, DOI 10.1007/s00281-019-00775-y

Kalantar-Zadeh K, 2020, ACS NANO, V14, P5179, DOI 10.1021/acsnano.0c03402

Keely S, 2012, MUCOSAL IMMUNOL, V5, P7, DOI 10.1038/mi.2011.55

Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490

Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001

Liang WC, 2020, GUT, V69, P1141, DOI 10.1136/gutjnl-2020-320832

Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013

MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M641

Minemura M, 2015, WORLD J GASTROENTERO, V21, P1691, DOI 10.3748/wjg.v21.i6.1691

Ostaff MJ, 2013, EMBO MOL MED, V5, P1465, DOI 10.1002/emmm.201201773

Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620

Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033

Pratelli A, 2008, VET J, V177, P71, DOI 10.1016/j.tvjl.2007.03.019

Proctor LM, 2011, CELL HOST MICROBE, V10, P287, DOI 10.1016/j.chom.2011.10.001

Roussos A, 2003, RESP MED, V97, P75, DOI 10.1053/rmed.2001.1409

Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x

Rutten EPA, 2014, CHEST, V145, P245, DOI 10.1378/chest.13-0584

Salazar N, 2017, GUT MICROBES, V8, P82, DOI 10.1080/19490976.2016.1256525

Schrezenmeir J, 2001, AM J CLIN NUTR, V73, p361S, DOI 10.1093/ajcn/73.2.361s

Song Y, 2020, GUT, V69, P1143, DOI 10.1136/gutjnl-2020-320891

Sun Z-P, 2020, STABILITY COVID 19 V, DOI [10.1101/2020.04.09.20058875, DOI 10.1101/2020.04.09.20058875]

Tai NW, 2015, REV ENDOCR METAB DIS, V16, P55, DOI 10.1007/s11154-015-9309-0

Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031

Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19

Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585

Wang HL, 2008, AM J EMERG MED, V26, P711, DOI 10.1016/j.ajem.2007.10.031

Wang J, 2014, J EXP MED, V211, P2397, DOI 10.1084/jem.20140625

Whittier CA, 2017, INT ENCY PRIMATOLOGY, P400

World Health Organization, 2003, CONS DOC EP SEV AC R

World Health Organization, 2020, WHO DIR GEN OP REM M

Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001

Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3

Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270

Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2

Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055

Xu PP, 2020, THERANOSTICS, V10, P6372, DOI 10.7150/thno.46833

Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582

Zhang H, 2020, GUT, V69, P1010, DOI 10.1136/gutjnl-2020-320953

Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238

Zhang TQ, 2020, J MED VIROL, V92, P909, DOI 10.1002/jmv.25795

Zhang Y, 2020, CHINA CDC WEEKLY, V2, P2019, DOI [10.46234/ccdcw2020.033, DOI 10.46234/CCDCW2020.033]

Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2

Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017

Kaynak Göster

Bibtex @araştırma makalesi { tbtkbiology943544, journal = {Turkish Journal of Biology}, issn = {1300-0152}, eissn = {1303-6092}, address = {}, publisher = {TÜBİTAK}, year = {2020}, volume = {44}, pages = {265 - 272}, doi = {}, title = {Gut-lung axis and dysbiosis in COVID-19}, key = {cite}, author = {Aktas, Busra and Aslım, Belma} }
APA Aktas, B , Aslım, B . (2020). Gut-lung axis and dysbiosis in COVID-19 . Turkish Journal of Biology , Special Issue on COVID-19 , 265-272 . Retrieved from
MLA Aktas, B , Aslım, B . "Gut-lung axis and dysbiosis in COVID-19" . Turkish Journal of Biology 44 (2020 ): 265-272 <>
Chicago Aktas, B , Aslım, B . "Gut-lung axis and dysbiosis in COVID-19". Turkish Journal of Biology 44 (2020 ): 265-272
RIS TY - JOUR T1 - Gut-lung axis and dysbiosis in COVID-19 AU - Busra Aktas , Belma Aslım Y1 - 2020 PY - 2020 N1 - DO - T2 - Turkish Journal of Biology JF - Journal JO - JOR SP - 265 EP - 272 VL - 44 IS - SI-1 SN - 1300-0152-1303-6092 M3 - UR - Y2 - 2020 ER -
EndNote %0 Turkish Journal of Biology Gut-lung axis and dysbiosis in COVID-19 %A Busra Aktas , Belma Aslım %T Gut-lung axis and dysbiosis in COVID-19 %D 2020 %J Turkish Journal of Biology %P 1300-0152-1303-6092 %V 44 %N SI-1 %R %U
ISNAD Aktas, Busra , Aslım, Belma . "Gut-lung axis and dysbiosis in COVID-19". Turkish Journal of Biology 44 / SI-1 (Haziran 2020): 265-272 .
AMA Aktas B , Aslım B . Gut-lung axis and dysbiosis in COVID-19. Turkish Journal of Biology. 2020; 44(SI-1): 265-272.
Vancouver Aktas B , Aslım B . Gut-lung axis and dysbiosis in COVID-19. Turkish Journal of Biology. 2020; 44(SI-1): 265-272.
IEEE B. Aktas ve B. Aslım , "Gut-lung axis and dysbiosis in COVID-19", Turkish Journal of Biology, c. 44, sayı. SI-1, ss. 265-272, Haz. 2020

6344 1638

Sayıdaki Diğer Makaleler

Phylogenetic analysis of SARS-CoV-2 genomes in Turkey


Gut-lung axis and dysbiosis in COVID-19

Busra AKTAS, Belma ASLIM

Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection


Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target


Covid-19: current knowledge, disease potential, prevention and clinical advances

Aftab ALAM, Mohd Faizan SİDDİQUİ, Nikhat IMAM, Rafat ALİ, Md MUSHTAQUE, Romana ISHRAT

Biosafety and biosecurity approaches to restrain/contain and counter SARS-CoV-2/COVID-19 pandemic: a rapid-review

Tauseef AHMAD, Haroon HAROON, Kuldecip DHAMA, Khan SHARUN, Fazal Mehmood KHAN, Irfan AHMED, Ruchi TİWARİ, Taha Hussien MUSA, Muhammad KHAN, D. Katterine BONİLLA-ALDANA, Alfonso J. RODRİGUEZ-MORALES, Jin HUİ

Identification of the nucleotide substitutions in 62 SARS-CoV-2 sequences from Turkey


An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19


Integration of transcriptomic profile of SARS-CoV-2 infected normal human bronchial epi-thelial cells with metabolic and protein-protein interaction networks

Hamza Umut KARAKURT, Pinar PİR

SARS-CoV-2 isolation and propagation from Turkish COVID-19 patients

Cihan TASTAN, Bulut YURTSEVER, Gozde Sir KARAKUS, Derya Dilek KANCAGİ, Sevda DEMİR, Selen ABANUZ, Utku SEYİS, Mulazim YİLDİRİM, Recai KUZAY, Omer ELİBOL, Serap ARBAK, Merve Acikel ELMAS, Selcuk BİRDOGAN, Osman Ugur SEZERMAN, Aye Sesin KOCAGOZ, Koray YALCİN, Ercument OVALİ